Familial Mediterranean Fever Pharmaceuticals Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Type (Colchicine, Interlukin-1 Inhibitors and Anti-IL-6 Drugs), By End Users (Hospitals, Clinical diagnostic laboratories, Other) and Region Forecast 2019-2030

Familial Mediterranean Fever Pharmaceuticals Market size was value US$ 1,682.8 million in 2023 and is projected to reach a value of US$ 2,305.4 million by 2030, at a CAGR of 4.6% from 2024-2030. Familial Mediterranean Fever (FMF) is the oldest and the most frequent autoinflammatory disease. It is a hereditary periodic fever syndrome characterized by self-limited episodes of fever and polyserositis associated with severe long-term complications, such as renal amyloidosis. FMF was particularly frequent in populations originating from the Mediterranean basin, such as Turks, Armenians, Jews, and Arabs. Familial Mediterranean fever (FMF) episodes manifest with symptoms such as high fever, severe abdominal pain, chest discomfort due to pleuritis, and swollen joints. These episodes typically last 1-3 days and recur irregularly.

Mutations in the MEFV gene, which encodes the protein pyrin, trigger inflammation, leading to the characteristic symptoms. Diagnosis involves clinical evaluation, review of medical history, and recognition of recurrent patterns. Genetic testing may be recommended for confirmation. The first attack usually occurs in early childhood. The majority (around 90%) of initial attacks occur by the end of the teenage years. In rare cases, FMF can develop later in life for the first time as well. According to most of the studies, there appears to be no significant difference in the incidence of FMF in males or females.

A nationwide survey in Turkey showed the ratio of the incidence of FMF was almost equal – male to female ratio of 1.2/1. The rise in the genetic mutations of the MEFV gene, the increased healthcare spending capability, advancements in the treatment and the availability of suitable drugs boost the markets. Additionally, the rise in personalized medicine and genetic treatments such as gene therapies helps the market even move up further. On the other hand, high cost associated with the treatment and availability of limited funds to initiate clinical trials are expected to obstruct the market growth. Complexity of the treatment limiting the immune response is projected to challenge the familial Mediterranean fever treatment market.